​​​​Global Coalition on Aging and Pfizer Medical Grants Partner to Tackle Vaccine Hesitancy in Super-Aging Japan

The unique partnership supports innovative research to increase use of recommended vaccines among Japan’s older adult population

New York, NEW YORK (February 17, 2021) – The Global Coalition on Aging and Pfizer Global Medical Grants announced today the launch of the first of its grant projects under the Japan-focused VALUE Initiative (Vaccines for All: Longevity Unleashed for Everyone), which has provided up to $1 million USD in grant awards. Grant recipients include Keio University, the Health and Global Policy Institute (HGPI), and the International Longevity Centre-UK. The three VALUE projects are poised to generate critical insights for both policy and practice about how to increase vaccine use among older adults and to better understand vaccine hesitancy in the Japanese context. The VALUE Initiative and its grantees will together contribute important evidence of how to extend the benefits of immunization to older adults at a critical global moment where immunizing adults is central and essential to relief from the Covid-19 pandemic.

The first VALUE project to launch, Moving the needle, Improving uptake of adult vaccination in Japan, is an innovative ethnographic initiative led by the International Longevity Centre – UK (ILC) and Stripe Partners.

“We are honored and delighted to see our first grantee – the ILC-UK and Stripe Partners – beginning work on their project, which is designed to increase the uptake of vaccinations for people aged 65 and over in Japan,” said Michael Hodin, CEO Global Coalition on Aging.  “When we conceived this grant program back in 2019 with Pfizer Global Medical Grants, we knew of the huge need to enhance adult vaccines as a critical part of prevention-focused health strategies in Japan, and therefore as a model for global lessons, especially as the WHO and UN were planning their launch of the Decade of Healthy Ageing.  And, now with older adults most at risk of severe illness and death from Covid-19 and the attendant need for their immunization, the importance of the program takes on an even greater sense of urgency.”

Immediate action is critical, especially as there will soon be 2 billion globally over 60, and, for the first time in the history of humanity, more old than young. When vaccines are not utilized or under-utilized, the result is an increased vulnerability to several diseases – including shingles, pneumococcal disease, and influenza. As we age, vaccinations can improve quality of life by reducing risks for morbidity and disability and have the potential to increase life expectancy, while having positive impacts on healthcare costs, especially hospitalization, readmissions and physician visits.

“VALUE is a very exciting initiative and a great example of the positive outcomes we can achieve through public/private partnerships,” said Dr. John Beard, Chair of the Global Coalition on Aging Advisory Council, former Director of Ageing and Life Course at the WHO, and member of the Expert Panel that evaluated grant proposals for the VALUE Initiative. “Linking VALUE to global interests in healthy and active aging through the WHO Decade of Healthy Ageing will enable us to learn from Japan even as this initiative contributes to better outcomes for Japan’s aging population itself.”

Along with Dr. Beard and Mr. Hodin, the VALUE Expert Panel includes Dr. Mitsunobu Kano, Okayama University; Dr. Bennett Lee, Pfizer Japan; Dr. Stefania Maggi, European Interdisciplinary Council on Aging; Dr. Kenji Shibuya, King’s College London; and Professor Brigita Skela-Savič, International Council of Nurses.

“By working in partnership with government leaders, NGOs, and professional health and medical associations, the VALUE Initiative will bring greater attention to the need, opportunity, and pathways for solutions and uncover strategies that can measurably increase the number of older adults who are immunized against preventable diseases,” said Hodin. “It is our hope that Japan can become a model for healthier longevity that developed and developing countries alike can follow.”

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

 

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Best Practices for Engaging a Multigenerational Workforce

Employers are grappling with a myriad of workforce-related issues ranging from productivity to attracting and retaining talent, but many may be overlooking some seismic shifts that are reshaping the future of work: longevity, population aging, and the multigenerational workforce.

Brazil Must Fight Antibiotic Resistance

The threat posed by antimicrobial resistance is urgent and spares no country - including Brazil. According to The Lancet, 63 deaths per 100,000 are associated with AMR in Brazil and Paraguay, a rate that exceeds the average for Latin America and the Caribbean. AMR-associated deaths in Brazil are second only to cardiovascular diseases and cancers.

More Than Half of Americans are Unfamiliar with Chronic Kidney Disease, Survey Finds

Chronic kidney disease (CKD) is a major blind spot for many Americans, a new survey suggests. The poll, conducted by the Global Coalition on Aging, asked 1,000 American adults about their understanding and perception of CKD. Though many respondents used the internet for medical information and had a regular doctor and blood work done once or twice a year, 58% of respondents said they were unfamiliar with the illness.

We Missed 100 Million Adult Vaccines – Here’s How We Get Back on Track

Like other pandemics throughout human history, COVID-19 has caused profound changes that are still rippling through our societies, even as people are understandably eager to move on. In fact, these impacts are all the more dangerous when they are largely ignored or effectively invisible. The decline in adult vaccination may be one of the most significant, as a new report finds that ~100 million doses were missed in 2021 and 2022 alone – reversing global progress towards widespread adult immunisation as a new standard of care in a world of more old than young.

New Analysis Shows Lost Ground on Adult Immunisation During the Pandemic with 100 Million Doses Potentially Missed

New data shared today by GSK, in collaboration with the IQVIA Institute for Human Data Science and the Global Coalition on Aging (GCOA), estimate approximately 100 million fewer doses of some adult vaccines (excluding Covid-19 vaccines) were administered in 2021 and 2022 than anticipated, based on the global vaccination adoption trends observed from 2013 to 2020, compounding already low adoption rates pre-pandemic.

Going Beyond Applause: The Potential of Caregiving to Unlock Job Opportunities of the Future

Early in the COVID-19 pandemic, the role of caregivers – staff and family who provide care for older and dependent people to carry out activities such as eating or moving - catapulted to the front of our collective conscience. The daily applause for front-line care workers showed a high level of recognition for their incredible work and provided insight into how our health systems must change as our society ages. We need to continue to recognise caregivers as essential to our ageing society.

High-Level Forum on the Silver Economy 2023

Join us for the High-Level Forum on the Silver Economy 2023. Now in its fourth year, the Silver Economy Forum 2023, December 6 and 7, will explore aging at every stage of life, looking at the growing global Silver Economy through a multigenerational lens. Linking to the goals and aspirations of the UN Decade of Healthy Ageing, SEF 2023 will highlight key themes at the intersection of aging at every age, and the Silver Economy.